About: Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.55 (+4.49%)
TPST NASDAQ Tempest Therapeutics Inc
Tempest Therapeutics Inc share price
Atividade de preço de TPST
Último preço
$ 0,550
Variação (24h)
0,02 USD (4,49%)
Volume
6.13K
Volume (média 4 sem.)
-
Abertura
$ 0,55
Variação do dia
$ 0,54 - $ 0,55
Fechamento anterior
$ 0,53
Último negócio
29 Oct, 1:36 pm GMT+0
Atrasado
29 Oct, 1:36 pm GMT+0
TPST price performance
Atrasado
29 Oct, 1:36 pm GMT+0
quote.marketSignals